Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD) reported financial results for 2021, achieving over $1 billion in annual revenue for the first time, reflecting a 21.5% increase from the prior year. The Omnipod product line generated $1.0 billion in revenue, with U.S. sales rising 23.6%. The company recorded an operating income of $126 million and a net income of $16.8 million. The recent clearance of the Omnipod 5 automated insulin delivery system by the U.S. FDA is a notable achievement. For 2022, Insulet expects revenue growth between 12% to 16% and a 100 basis point increase in operating margins.

Insulet Corporation (NASDAQ: PODD) launches a unique initiative integrating diabetes representation into the video game Animal Crossing: New Horizons. Players can download designs for insulin pump outfits and access Omnipod Bay, a themed island promoting diabetes awareness through playful activities. A recent survey revealed that 94% of people with type 1 diabetes value cultural representation, yet 51% feel underrepresented. The launch event takes place today at 3:00 PM ET, featuring content creators raising funds for JDRF, with Insulet matching donations.

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two investor conferences in March 2022. The first is the Raymond James 43rd Annual Institutional Investors Conference on March 7 at 1:05 PM ET, followed by the Cowen 42nd Annual Health Care Conference on March 8 at 9:50 AM ET. Live webcasts will be available on their website, along with replays post-event. Insulet aims to simplify insulin delivery with its innovative Omnipod system.

Insulet Corporation (NASDAQ: PODD) announces the appointment of Elizabeth “Bess” Weatherman to its Board of Directors, effective immediately. Weatherman, a Special Limited Partner at Warburg Pincus, has extensive experience in healthcare investment and leadership. She will stand for election at the 2022 Annual Meeting and join the Compensation Committee. The company also announced David Lemoine's retirement from the Board in May after six years of service. Insulet aims to enhance its growth strategies with this new appointment.

Insulet Corporation (NASDAQ: PODD) has received FDA clearance for its Omnipod® 5 Automated Insulin Delivery System, aimed at individuals aged six and older with type 1 diabetes. This system is the first tubeless automated insulin delivery technology that integrates with the Dexcom G6 Continuous Glucose Monitoring system, allowing automatic insulin adjustments to help manage blood sugar levels effectively. Omnipod 5 will be launched through pharmacies, with a limited market release planned to gather insights for product enhancement.

Insulet Corporation (NASDAQ: PODD) will announce its fourth quarter and full year financial results for 2021 on February 23, 2022, after market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day. The call will be accessible through the Investor Relations section of the company's website, and a replay will be available post-event. Insulet specializes in tubeless insulin pump technology under its Omnipod brand, offering innovative solutions for diabetes management and expanding to deliver non-insulin medications.

Insulet Corporation (NASDAQ: PODD) announced its participation in the 45th Nasdaq Investor Conference on December 3, 2021, at 11:30 a.m. ET. The presentation will be held virtually, and investors can access the live webcast at investors.insulet.com/events, with a replay available post-event. Insulet is renowned for its tubeless insulin pump technology through its Omnipod product line, focusing on simplifying diabetes management with its innovative, needle-free delivery system.

Insulet Corporation (NASDAQ: PODD) reported strong third-quarter results for the period ending September 30, 2021, with revenues of $275.6 million, reflecting a 17.8% year-over-year increase. Notably, Omnipod revenue surged to $260.3 million, a growth of 22.7%. Operating income reached $33.7 million with a gross margin of 68.5%. Despite a 30.1% decline in Drug Delivery revenue, net income rose to $12.6 million. The company also updated its revenue guidance for the year to 18%-20% growth and confirmed a low double-digit operating margin expectation.